🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Quanterix Corporation QTRX R2K

Healthcare · Medical Devices · United States
https://www.quanterix.com

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

READ MORE ›
$3.06
-41.15% 1Y

Market & Price

Market Cap
$144.14M
Current Price
$3.06
High / Low (52W)
$8.06 / $2.51
Beta
1.15

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.00
Price to Book
0.51
P/S
0.99
EV/EBITDA
-1.26
Dividend Yield
-

Profitability & Returns

ROCE
-31.92%
ROE
-34.81%
ROA
-13.39%
Profit Margin
-71.86%
Op Margin
-59.12%
EPS (Latest Qtr)
$-0.37
EPS (TTM)
$-2.35

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
2.54
Current Ratio
3.72
Debt
$35.34M
Total Assets
$418.77M
Current Assets
$212.26M
Working Capital
$137.50M

Ownership

Promoter Holding
6.24%
Chg in Prom Hold
-
FII / Inst Holding
85.44%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$80.22M
Total Revenue (TTM)
$144.98M
EBITDA
$-63.67M
Free Cash Flow
$-21.98M
Operating Cash Flow
$-81.45M
Shares Outstanding
47.11M
Gross Margin
45.31%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
9.73%
Profit 5Y
-2.54%
Revenue (YoY)
20.10%
Earnings (YoY)
-

PROS

No notable strengths flagged.

CONS

  • Earnings shrank at -2.5% CAGR over 5 years.
  • Trading 62.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 QTRX Quanterix Corporation R2K 3.06 - $144.14M - -31.92% -34.81% 9.73% -2.54%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ----7.52M8.64M10.59M10.88M12.34M13.54M14.94M15.92M15.73M13.13M31.39M26.13M27.21M25.37M27.69M29.55M23.50M26.65M28.46M31.03M31.56M32.07M34.38M35.81M-30.33M24.45M40.15M43.78M36.41M
Cost of Revenue -----------------------------15.49M13.18M23.03M23.82M20.85M
Gross Profit --2.56M-3.17M3.97M5.59M5.21M6.01M6.93M7.03M6.87M6.81M5.21M21.11M15.05M16.35M13.87M15.24M14.56M8.71M10.94M16.93M19.14M19.41M18.55M22.23M20.15M-14.84M11.28M17.12M19.96M15.57M
Operating Expenses -----------------------------41.20M40.71M47.27M43.83M37.09M
Operating Income -6.06M-6.47M-6.39M-7.09M-7.16M-7.31M-7.66M-9.41M-9.36M-10.51M-10.24M-11.49M-11.73M-12.20M2.28M-9.93M-9.79M-13.67M-15.23M-18.19M-24.96M-36.60M-9.42M-9.56M-12.81M-15.16M-10.94M-11.75M--26.37M-29.43M-30.15M-23.87M-21.53M
EBITDA ------------------------------24.18M-26.58M-25.57M-14.56M-15.92M
Interest Expense ----------------------------------
Pretax Income ------------------------------23.42M-30.09M-36.00M-22.77M-17.55M
Tax Provision ------------------------------2.91M-73.00K-2.48M345.00K-7.00K
Net Income -6.39M-6.63M-6.61M-7.38M-7.20M-7.34M-7.66M-9.33M-9.40M-10.56M-9.87M-10.96M-11.61M-12.30M2.20M-9.82M-10.10M-11.90M-15.66M-18.15M-24.90M-35.06M-7.27M-5.55M-6.72M-11.16M-7.39M-8.35M--20.50M-30.01M-33.52M-23.12M-17.54M
Diluted EPS -----------0.37--0.41-0.430.07-0.31-0.29-0.33-0.43-0.49-0.67-0.95-0.16-0.16-0.18-0.29-0.19-0.22--0.53-0.77-0.73-0.49-0.37
R&D Expense 4.25M3.90M4.22M3.93M3.64M3.71M4.41M4.04M3.85M4.02M3.92M4.40M4.27M4.31M5.38M6.22M6.68M6.75M6.81M7.03M6.62M6.63M4.72M5.95M7.74M6.74M8.17M8.10M-10.04M9.08M8.01M-7.32M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -22.87M37.63M56.73M86.38M-104.95M121.14M135.44M138.65M
Cost of Revenue ------60.16M48.14M54.32M73.94M
Gross Profit 7.75M9.99M17.95M26.84M48.18M-44.79M73.00M81.12M64.72M
Operating Expenses ------119.50M117.66M133.74M174.53M
Operating Income -21.71M-26.00M-31.55M-41.60M-31.58M--74.71M-44.66M-52.62M-109.81M
EBITDA -------68.58M-36.37M-44.26M-90.89M
Interest Expense ----------
Pretax Income -------99.41M-27.64M-38.10M-112.27M
Tax Provision ------164.00K719.00K434.00K-5.12M
Net Income -23.17M-27.02M-31.54M-40.80M-31.53M--99.57M-28.35M-38.53M-107.15M
Diluted EPS ----1.63-1.07--2.61-0.75-1.00-2.51
R&D Expense 16.99M16.30M15.80M16.19M20.17M27.98M26.81M26.06M31.08M35.92M

Compounded Sales Growth

5 Years:9.73%
1 Year:20.10%

Compounded Profit Growth

5 Years:-2.54%
1 Year:-

Stock Price Performance

1 Year:-41.15%
6 Months:-57.68%
3 Months:-53.28%
1 Month:+0.33%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --91.78M67.61M169.95M271.05M-433.58M428.57M406.53M418.77M
Current Assets -------381.52M382.10M363.59M212.26M
Cash & Equivalents --79.68M44.43M109.16M181.58M-338.74M174.42M56.71M29.84M
Inventory -------16.96M26.12M32.77M54.76M
Receivables -------19.02M25.41M32.14M29.97M
Total Liabilities --25.91M26.55M41.29M64.92M-75.65M78.61M76.50M123.04M
Current Liabilities --19.71M18.12M19.83M39.80M-31.35M38.98M42.01M74.76M
Long Term Debt --4.35M7.62M7.59M------
Total Debt -------44.10M41.46M37.37M37.24M
Total Equity -88.64M-115.11M65.87M41.06M128.66M206.12M-357.93M349.96M330.04M295.73M
Shares Outstanding -------37.28M38.01M38.54M46.74M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.74M-22.11M-28.72M-26.19M-23.36M--48.61M-18.85M-35.16M-77.24M
Investing Cash Flow -826.00K-1.13M-5.45M-25.38M-626.00K--11.09M-148.45M-82.27M50.23M
Financing Cash Flow 45.92M73.25M-78.00K116.20M96.24M-2.31M2.69M456.00K-708.00K
Capital Expenditure -526.00K-1.13M-1.52M-10.85M-3.93M--11.61M-3.84M-3.37M-2.61M
Free Cash Flow -18.27M-23.24M-30.24M-37.03M-27.30M--60.23M-22.69M-38.53M-79.85M
Net Change in Cash -------57.39M-164.61M-116.97M-27.71M

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -43.7%47.7%47.3%55.8%-42.7%60.3%59.9%46.7%
Operating Margin % --113.7%-83.8%-73.3%-36.6%--71.2%-36.9%-38.8%-79.2%
Net Margin % --118.1%-83.8%-71.9%-36.5%--94.9%-23.4%-28.4%-77.3%
ROE % 20.1%-41.0%-76.8%-31.7%-15.3%--27.8%-8.1%-11.7%-36.2%
ROCE % --36.1%-63.8%-27.7%-13.7%--18.6%-11.5%-14.4%-31.9%

Shareholding Pattern

Insiders
6.24%
Institutions
85.44%
Public Float
91.13%

Top Institutional Holders

#Holder% HeldSharesValue
1 Ameriprise Financial, Inc. 7.52% 3.54M $10.84M
2 Blackrock Inc. 6.96% 3.28M $10.03M
3 Portolan Capital Management, LLC 6.25% 2.95M $9.01M
4 Blue Water Life Science Advisors, Lp 4.55% 2.14M $6.55M
5 William Blair Investment Management, LLC 4.42% 2.08M $6.38M
6 Invenomic Capital Management, LP 4.10% 1.93M $5.91M
7 Vanguard Capital Management LLC 3.79% 1.78M $5.46M
8 Levin Capital Strategies, LP 3.11% 1.46M $4.48M
9 First Eagle Investment Management, LLC 2.76% 1.30M $3.98M
10 Geode Capital Management, LLC 2.11% 994.76K $3.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for QTRX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks